US Broker Ratings

MBX Biosciences, Inc. (MBX) Investor Outlook: Exploring a 166% Potential Upside

Investors are increasingly turning their attention to MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company that is pioneering innovative treatments in the healthcare sector. With a remarkable potential upside..

Evolus, Inc. Common Stock (EOLS)

⚠️ No article content returned.

..

Verastem, Inc. (VSTM) Stock Analysis: A 75% Upside Potential in the Biotech Sector

Verastem, Inc. (NASDAQ: VSTM), a U.S.-based biopharmaceutical company, is catching the eye of investors with its impressive potential upside of 75.26%, according to recent analyst ratings. As a development-stage company..

OrthoPediatrics Corp. (KIDS) Stock Analysis: Unveiling a 76.8% Potential Upside in Pediatric Orthopedics

OrthoPediatrics Corp. (NASDAQ: KIDS) is positioning itself as a key player in the pediatric orthopedics market, offering specialized medical devices designed specifically for children. With a current market capitalization of..

Cogent Biosciences, Inc. (COGT): Investor Outlook Highlights 70% Potential Upside

Cogent Biosciences, Inc. (NASDAQ: COGT) is currently capturing the attention of investors with its promising potential upside and strategic focus on precision therapies for genetically defined diseases. Headquartered in Waltham,..

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: Exploring a Potential 144% Upside in the Rare Disease Market

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a commercial-stage biotechnology company, is gaining investor attention with a notable potential upside of 144.18%. Specializing in the development of treatments for rare diseases through..

Abivax SA (ABVX) Stock Analysis: Exploring a 27.8% Potential Upside in the Biotech Frontier

Abivax SA (ABVX), a French biotechnology company, is capturing attention in the investment community with its promising potential upside of 27.8%, as indicated by analyst ratings. Specializing in developing therapeutics..

AngioDynamics, Inc. (ANGO) Stock Analysis: A 101% Potential Upside Ignites Investor Interest

AngioDynamics, Inc. (NASDAQ: ANGO), a significant player in the healthcare sector specializing in medical instruments and supplies, presents a compelling case for investors with a potential upside of 101.21%. With..

Altimmune, Inc. (ALT) Stock Analysis: Exploring a 387% Potential Upside in the Biotech Sector

Altimmune, Inc. (NASDAQ: ALT), a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, is making waves in the biotechnology sector. With a focus on developing innovative treatments for obesity, metabolic, and..

Embecta Corp. (EMBC) Stock Analysis: Assessing a 20% Potential Upside for Investors

For investors with a keen eye on the healthcare sector, Embecta Corp. (NASDAQ: EMBC) presents a compelling opportunity with its focus on diabetes management solutions. Based in Parsippany, New Jersey,..

Oric Pharmaceuticals, Inc. (ORIC) Stock Analysis: Exploring 85.76% Potential Upside in Biotech Innovator

Oric Pharmaceuticals, Inc. (NASDAQ: ORIC) stands out in the competitive biotechnology landscape with its promising pipeline aimed at addressing cancer resistance mechanisms, a challenging frontier in oncology. With a market..

Tyra Biosciences, Inc. (TYRA): Analyst Consensus Unveils a 157% Potential Upside

Investors seeking opportunities in the biotechnology sector may find Tyra Biosciences, Inc. (NASDAQ: TYRA) an intriguing prospect. With its focus on precision medicines targeting fibroblast growth factor receptor (FGFR) biology,..

Humacyte, Inc. (HUMA) Stock Analysis: Exploring a Potential 500% Upside in Biotechnology

Investors eyeing the biotechnology sector may find Humacyte, Inc. (NASDAQ: HUMA) an intriguing proposition, especially with a potential upside of 500.65% as indicated by analyst target prices. As of recent..

Akso Health Group (AHG) Stock Analysis: Navigating a 415.8% Revenue Growth Surge

Akso Health Group (NASDAQ: AHG), a key player in China’s burgeoning healthcare sector, is turning heads with its remarkable 415.8% revenue growth. Despite the lack of traditional valuation metrics like..

Inventiva S.A. (IVA) Stock Analysis: Exploring a 155.76% Potential Upside for Investors

Investors looking for opportunities in the biotechnology sector may find Inventiva S.A. – American Depositary Shares (IVA) an intriguing prospect, with a notable potential upside of 155.76%. Headquartered in Daix,..

Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 179.97% Upside in the Biotech Sector

Upstream Bio, Inc. (NASDAQ: UPB) is making waves in the biotechnology sector, capturing the attention of investors with its promising potential upside of 179.97%. This clinical-stage biotech company, headquartered in..

Dianthus Therapeutics (DNTH) Stock Analysis: Strong Buy Ratings and 122% Potential Upside

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is capturing significant attention within the biotechnology sector, an industry known for its groundbreaking innovations and high-stakes ventures. As a clinical-stage biotechnology company headquartered in..

Tectonic Therapeutic, Inc. (TECX) Stock Analysis: Exploring a Potential 213.90% Upside in Biotechnology

Investors looking for promising opportunities in the biotechnology sector may find Tectonic Therapeutic, Inc. (NASDAQ: TECX) an intriguing prospect. With a current market capitalization of $475.19 million, this Watertown, Massachusetts-based..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: An 18.58% Potential Upside for Investors in the Biotech Sector

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) is capturing the attention of investors with an attractive potential upside of 18.58%. As a commercial-stage biopharmaceutical company, Xeris is strategically positioned in the..

Owens & Minor, Inc. (OMI) Stock Analysis: Exploring a 23.69% Potential Upside in the Healthcare Sector

Owens & Minor, Inc. (NYSE: OMI) operates within the healthcare sector, specifically in the medical distribution industry, offering an array of products and services critical to healthcare providers and patients..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds